SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

trastuzumab emtansine

VIVS·VivoSim Labs, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market since 2013.
Why 4/10
Kadcyla is already approved and marketed. No new PDUFA or pivotal Phase 3 readout is scheduled in the next 12 months. For Roche (RHHBY), Kadcyla is one of many products in a large, diversified portfolio, so even a significant label change or competitive shift would not drive a binary share-price move.
Actionable Insight NEUTRAL

The VIVS filing hint is a dead end, VivoSim Labs does not develop trastuzumab emtansine. Investors focused on this drug should watch Roche (RHHBY) for Kadcyla sales trends and competition from Enhertu (AZN/Daiichi), not VIVS. There is no near-term binary catalyst for Kadcyla.

Price Chart

Loading chart...

Executive Summary

Trastuzumab emtansine (brand name Kadcyla) is an already-approved antibody-drug conjugate (ADC) developed by Genentech (Roche, traded OTC as RHHBY). Originally FDA-approved in February 2013 for HER2-positive metastatic breast cancer, it received a supplemental FDA approval in May 2025. The filing hint pointing to VivoSim Labs (VIVS) is misleading, VIVS is a separate micro-cap biotech with a drug-toxicity testing platform that only mentioned the drug in a benchmark comparison press release; it does not develop or own Kadcyla. For Roche, Kadcyla is one of many marketed products, faces growing competition from second-generation ADCs like Enhertu, and has no imminent binary regulatory catalyst.

How It Works

Kadcyla is an antibody-drug conjugate (ADC), think of it as a targeted missile. The antibody part (trastuzumab) latches onto HER2 proteins that are overexpressed on certain cancer cells, then the attached chemotherapy payload (emtansine/DM1) is released directly inside the cancer cell to kill it.

Trial Status

Kadcyla was originally FDA-approved in February 2013 for HER2-positive metastatic breast cancer. It received a supplemental FDA approval in May 2025. Completed and ongoing Phase 2 trials are exploring its use in additional HER2-amplified solid tumor types. A safety labeling update was made in April 2026 adding boxed warnings for hepatotoxicity, cardiac toxicity, and embryo-fetal toxicity.

The Two-Sided Case

▲ Bull Case3
Kadcyla is an established, approved ADC with over a decade of clinical data supporting its safety and efficacy in HER2-positive breast cancer.
The supplemental FDA approval in May 2025 suggests ongoing label expansion efforts by Genentech/Roche.
As one of the first ADCs to market, it has strong brand recognition and a well-established reimbursement pathway.
▼ Bear Case4
Kadcyla faces intense competition from Enhertu (trastuzumab deruxtecan, AstraZeneca/Daiichi Sankyo), which has demonstrated superior efficacy in head-to-head trials including DESTINY-Breast03.
The April 2026 FDA safety labeling update added boxed warnings for hepatotoxicity, cardiac toxicity, and embryo-fetal toxicity, reflecting serious safety concerns.
For Roche, Kadcyla is not a pipeline-driving binary event, it is an already-commercialized product in a large portfolio, limiting any single-product stock impact.
The VIVS filing hint is entirely misleading, VivoSim Labs does not develop or own this drug and is a separate micro-cap with a market cap reflected in a ~$0.15 stock price.

Upcoming Catalysts

  • Kadcyla commercial sales performance in Roche's quarterly earnings reports
  • Potential new trial readouts in additional HER2-amplified tumor types
  • Competitive dynamics versus Enhertu (trastuzumab deruxtecan) in the HER2-positive breast cancer market

Source Filing

The SecBot filing or press-release report that triggered this drug report:

VivoSim Labs, Inc. Press Release VIVS ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 sec.gov